Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy

Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall survival in patients with castration-resistant prostate cancer (CRPC) and bone metastases. We aimed to assess feasibility of Ra-223 treatment in patients with metastatic hormone-sensitive prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenter, Vera, Herlemann, Annika, Fendler, Wolfgang P., Ilhan, Harun, Tirichter, Natalia, Bartenstein, Peter, Stief, Christian G., la Fougère, Christian, Albert, Nathalie L., Rominger, Axel, Gratzke, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546468/
https://www.ncbi.nlm.nih.gov/pubmed/28484088
http://dx.doi.org/10.18632/oncotarget.17311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546468/
https://www.ncbi.nlm.nih.gov/pubmed/28484088
http://dx.doi.org/10.18632/oncotarget.17311

Ejemplares similares